Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:2 Issue:3 Number:100 ISSN#:2563-5476
RCT
ACE Report #4798
Ace Report Cover Spine

ISASS: Improved 1-year outcome with Superion and X-STOP devices for lumbar spinal stenosis


How to Cite

OrthoEvidence. ISASS: Improved 1-year outcome with Superion and X-STOP devices for lumbar spinal stenosis. ACE Report. 2013;2(3):100. Available from: https://myorthoevidene.com/AceReport/Report/4798

Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A

Prospective, randomized, multicenter study comparing the clinical outcomes of two minimally invasive interspinous devices for the treatment of lumbar spinal stenosis

Contributing Authors: WD Bradley PG Whang

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

CONFERENCE ACE REPORTS

This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.

Synopsis

416 patients were randomized to receive either the Superion or X-STOP interspinous systems in minimally invasive surgery for symptomatic treatment of lumbar spinal stenosis. The objective of the study was to determine if there was a difference in clinical outcomes of the two devices at 12 months of a 5 year trial. The results at 1 year follow-up indicated that both treatment devices significantly ...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.